المؤلفون: Suh DC; a Department of Pharmacy , Chung-Ang University College of Pharmacy , Seoul , South Korea., Griggs SK; b St Louis College of Pharmacy , Pharmacy Administration , St. Louis , MO , USA.; c St. Louis College of Pharmacy , Center for Outcomes Research and Education , St. Louis , MO , USA.; e Saint Louis University Center for Outcomes Research (SLUCOR) , St. Louis , MO , USA., Henderson ER; d Saint Louis University , Health Outcomes and Research and Evaluation Sciences , St. Louis , MO , USA.; e Saint Louis University Center for Outcomes Research (SLUCOR) , St. Louis , MO , USA., Lee SM; a Department of Pharmacy , Chung-Ang University College of Pharmacy , Seoul , South Korea., Park T; b St Louis College of Pharmacy , Pharmacy Administration , St. Louis , MO , USA.; c St. Louis College of Pharmacy , Center for Outcomes Research and Education , St. Louis , MO , USA.; e Saint Louis University Center for Outcomes Research (SLUCOR) , St. Louis , MO , USA.

المصدر: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2018 Feb; Vol. 18 (1), pp. 51-69. Date of Electronic Publication: 2017 Nov 22.

نوع المنشور: Comparative Study; Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8379 (Electronic) Linking ISSN: 14737167 NLM ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Subsets: MEDLINE

مواضيع طبية MeSH: Anticholesteremic Agents/*therapeutic use , Cardiovascular Diseases/*prevention & control , Hypercholesterolemia/*drug therapy, Anticholesteremic Agents/administration & dosage ; Anticholesteremic Agents/economics ; Cardiovascular Diseases/economics ; Cost-Benefit Analysis ; Drug Costs ; Drug Therapy, Combination ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/economics ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia/complications ; Hypercholesterolemia/economics ; PCSK9 Inhibitors ; Treatment Outcome